Skip to main content

Table 2 Multivariate Cox regression model for CRPC and overall mortality risk with PSAT½ groups as parameters

From: Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

   CRPC Overall mortality  
Univariate Multivariate Univariate Multivariate
p-value HR 95% CI p-value p-value HR 95% CI p-value
Age Continuous 0.204 0.995 0.970–1.022 0.734 0.243 1.046 0.990–1.105 0.107
Initial PSA ≥20 ng/mL 0.170     0.154    
Gleason score >7 0.013* 1.472 1.018–2.128 0.040* 0.006* 3.127 1.361–7.187 0.007*
PSAT½ (days) Non-responder (below 0) (reference)     (reference)    
Ultra-rapid responder (0~15) 0.279 0.702 0.390–1.263 0.238 0.189 0.443 0.168–1.164 0.099
Rapid responder (15~30) 0.011* 0.499 0.271–0.920 0.026* 0.018* 0.295 0.109–0.797 0.016*
Intermediate responder (30~45) 0.007* 0.397 0.191–0.823 0.013* 0.011* 0.138 0.033–0.584 0.007*
Slow responder (over 45) 0.032* 0.553 0.289–1.057 0.070 0.094 0.501 0.183–1.368 0.177
Pathologic T stage Below T2 (reference)     (reference)    
T3 0.915 0.966 0.634–1.471 0.870 0.013* 4.987 1.187–20.946 0.028*
T4 0.034* 1.831 0.921–3.642 0.085 0.009* 9.521 1.799–50.402 0.008*
ADT exposure duration (days) Continuous 0.169     0.386    
  1. HR hazard ratio, CI confidence interval, PSA prostate-specific antigen, ADT androgen deprivation therapy, PSAT ½ prostate-specific antigen half-life
  2. *statistically significant at p < 0.05